NASDAQ:XBIO Xenetic Biosciences (XBIO) Stock Forecast, Price & News $3.19 +0.05 (+1.59%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$3.11▼$3.2450-Day Range$2.66▼$5.1852-Week Range$2.40▼$10.00Volume10,280 shsAverage Volume64,619 shsMarket Capitalization$4.85 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Xenetic Biosciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,153.9% Upside$40.00 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.61) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 stars 3.0 Analyst's Opinion Consensus RatingXenetic Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, Xenetic Biosciences has a forecasted upside of 1,153.9% from its current price of $3.19.Amount of Analyst CoverageXenetic Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.06% of the float of Xenetic Biosciences has been sold short.Short Interest Ratio / Days to CoverXenetic Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenetic Biosciences has recently decreased by 77.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXenetic Biosciences does not currently pay a dividend.Dividend GrowthXenetic Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XBIO. Previous Next 3.0 News and Social Media Coverage News SentimentXenetic Biosciences has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Xenetic Biosciences this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Xenetic Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Xenetic Biosciences is held by insiders.Percentage Held by InstitutionsOnly 16.28% of the stock of Xenetic Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xenetic Biosciences are expected to grow in the coming year, from ($4.61) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenetic Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenetic Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenetic Biosciences has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xenetic Biosciences (NASDAQ:XBIO) StockXenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Read More Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIO Stock News HeadlinesMay 16, 2023 | americanbankingnews.comXenetic Biosciences (NASDAQ:XBIO) Downgraded by HC WainwrightMay 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 31, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 6, 2023 | americanbankingnews.comReviewing Xenetic Biosciences (NASDAQ:XBIO) & Artelo Biosciences (NASDAQ:ARTL)May 5, 2023 | morningstar.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarMay 4, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentMay 3, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonMay 2, 2023 | americanbankingnews.comLeap Therapeutics (NASDAQ:LPTX) vs. Xenetic Biosciences (NASDAQ:XBIO) Head to Head ContrastMay 31, 2023 | Legacy Research (Affiliate) (Ad)Bear market expert makes new predictionNobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.April 18, 2023 | americanbankingnews.comXenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 24.3% in MarchApril 13, 2023 | americanbankingnews.comXenetic Biosciences (NASDAQ:XBIO) Earns Buy Rating from HC WainwrightApril 12, 2023 | msn.comHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationApril 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)April 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformMarch 29, 2023 | americanbankingnews.comXenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Growth in Short InterestMarch 28, 2023 | americanbankingnews.comXenetic Biosciences Inc to Post Q1 2023 Earnings of ($0.11) Per Share, HC Wainwright Forecasts (NASDAQ:XBIO)March 16, 2023 | finanznachrichten.deJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesMarch 16, 2023 | finance.yahoo.comJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesFebruary 23, 2023 | seekingalpha.comXBIO Xenetic Biosciences, Inc.February 21, 2023 | reuters.comXBIO.PH - | Stock Price & Latest News | ReutersJanuary 17, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with ChemotherapyDecember 15, 2022 | finance.yahoo.comWhy We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At AllDecember 1, 2022 | finance.yahoo.comThis Is Why Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Looks AppropriateNovember 12, 2022 | finance.yahoo.comXenetic Biosciences Third Quarter 2022 Earnings: Beats ExpectationsSeptember 7, 2022 | finance.yahoo.comXenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 12, 2022 | finance.yahoo.comXenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business UpdateJune 2, 2022 | finance.yahoo.comXenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology EventSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIO Company Calendar Last Earnings3/23/2023Today5/30/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XBIO CUSIPN/A CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees4Year Founded2011Price Target and Rating Average Stock Price Forecast$40.00 High Stock Price Forecast$40.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+1,153.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,550,000.00 Net Margins-302.29% Pretax Margin-302.23% Return on Equity-41.39% Return on Assets-38.47% Debt Debt-to-Equity RatioN/A Current Ratio15.04 Quick Ratio15.04 Sales & Book Value Annual Sales$1.71 million Price / Sales2.84 Cash FlowN/A Price / Cash FlowN/A Book Value$9.00 per share Price / Book0.35Miscellaneous Outstanding Shares1,520,000Free Float1,403,000Market Cap$4.85 million OptionableNot Optionable Beta2.76 Social Links Key ExecutivesMr. Jeffrey F. Eisenberg (Age 53)CEO & Director Mr. James F. Parslow (Age 54)CFO, COO & Corp. Sec. Dr. Curtis A. Lockshin (Age 59)Chief Scientific Officer Key CompetitorsInMed PharmaceuticalsNASDAQ:INMSonoma PharmaceuticalsNASDAQ:SNOALexaria BioscienceNASDAQ:LEXXTimber PharmaceuticalsNYSE:TMBRClearmind MedicineNASDAQ:CMNDView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 52,779 shares on 5/16/2023Ownership: 0.513%Renaissance Technologies LLCSold 43,893 shares on 5/12/2023Ownership: 0.656%View All Institutional Transactions XBIO Stock - Frequently Asked Questions Should I buy or sell Xenetic Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares. View XBIO analyst ratings or view top-rated stocks. What is Xenetic Biosciences' stock price forecast for 2023? 1 equities research analysts have issued 12 month price targets for Xenetic Biosciences' stock. Their XBIO share price forecasts range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 1,153.9% from the stock's current price. View analysts price targets for XBIO or view top-rated stocks among Wall Street analysts. How have XBIO shares performed in 2023? Xenetic Biosciences' stock was trading at $2.8510 at the beginning of the year. Since then, XBIO stock has increased by 11.9% and is now trading at $3.19. View the best growth stocks for 2023 here. Are investors shorting Xenetic Biosciences? Xenetic Biosciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 800 shares, a decrease of 77.8% from the April 30th total of 3,600 shares. Based on an average daily trading volume, of 19,900 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the company's shares are sold short. View Xenetic Biosciences' Short Interest. When is Xenetic Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our XBIO earnings forecast. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences Inc (NASDAQ:XBIO) released its earnings results on Thursday, March, 23rd. The company reported ($1.00) earnings per share for the quarter. The business earned $0.49 million during the quarter, compared to the consensus estimate of $0.18 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 41.39% and a negative net margin of 302.29%. When did Xenetic Biosciences' stock split? Xenetic Biosciences's stock reverse split before market open on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX). What is Xenetic Biosciences' stock symbol? Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO." Who are Xenetic Biosciences' major shareholders? Xenetic Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.66%) and Susquehanna International Group LLP (0.51%). How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xenetic Biosciences' stock price today? One share of XBIO stock can currently be purchased for approximately $3.19. How much money does Xenetic Biosciences make? Xenetic Biosciences (NASDAQ:XBIO) has a market capitalization of $4.85 million and generates $1.71 million in revenue each year. The company earns $-6,550,000.00 in net income (profit) each year or ($4.10) on an earnings per share basis. How can I contact Xenetic Biosciences? Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The official website for the company is www.xeneticbio.com. The company can be reached via phone at 781-778-7720 or via email at xbio@jtcir.com. This page (NASDAQ:XBIO) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.